CA2702650C — Phenyl amino pyrimidine compounds and uses thereof
Assigned to GlaxoSmithKline LLC · Expires 2017-01-03 · 9y expired
What this patent protects
The present disclosure relates to phenyl amino pyrimidine compounds comprising the following general formula: (See Formula I) which are inhibitors of JAK kinases. In particular the compounds are selective for JAK2 kinases as compared to JAK3.
USPTO Abstract
The present disclosure relates to phenyl amino pyrimidine compounds comprising the following general formula: (See Formula I) which are inhibitors of JAK kinases. In particular the compounds are selective for JAK2 kinases as compared to JAK3.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.